388 related articles for article (PubMed ID: 31542876)
1. Research-based PAM50 signature and long-term breast cancer survival.
Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes.
Caan BJ; Sweeney C; Habel LA; Kwan ML; Kroenke CH; Weltzien EK; Quesenberry CP; Castillo A; Factor RE; Kushi LH; Bernard PS
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):725-34. PubMed ID: 24521998
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.
Klopfenstein Q; Derangère V; Arnould L; Thibaudin M; Limagne E; Ghiringhelli F; Truntzer C; Ladoire S
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083415
[TBL] [Abstract][Full Text] [Related]
5. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
[TBL] [Abstract][Full Text] [Related]
6. PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.
Wang L; Li Q; Aushev VN; Neugut AI; Santella RM; Teitelbaum S; Chen J
Breast Cancer; 2021 Nov; 28(6):1235-1242. PubMed ID: 34003448
[TBL] [Abstract][Full Text] [Related]
7. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
[TBL] [Abstract][Full Text] [Related]
8. PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.
Tobin NP; Lundberg A; Lindström LS; Harrell JC; Foukakis T; Carlsson L; Einbeigi Z; Linderholm BK; Loman N; Malmberg M; Fernö M; Czene K; Perou CM; Bergh J; Hatschek T;
Clin Cancer Res; 2017 Dec; 23(23):7225-7231. PubMed ID: 28972041
[No Abstract] [Full Text] [Related]
9. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.
Picornell AC; Echavarria I; Alvarez E; López-Tarruella S; Jerez Y; Hoadley K; Parker JS; Del Monte-Millán M; Ramos-Medina R; Gayarre J; Ocaña I; Cebollero M; Massarrah T; Moreno F; García Saenz JA; Gómez Moreno H; Ballesteros A; Ruiz Borrego M; Perou CM; Martin M
BMC Genomics; 2019 Jun; 20(1):452. PubMed ID: 31159741
[TBL] [Abstract][Full Text] [Related]
11. A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival.
Jaber MI; Song B; Taylor C; Vaske CJ; Benz SC; Rabizadeh S; Soon-Shiong P; Szeto CW
Breast Cancer Res; 2020 Jan; 22(1):12. PubMed ID: 31992350
[TBL] [Abstract][Full Text] [Related]
12. Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
Bustamante Eduardo M; Popovici V; Imboden S; Aebi S; Ballabio N; Altermatt HJ; Günthert A; Jaggi R
BMC Cancer; 2019 Jun; 19(1):549. PubMed ID: 31174485
[TBL] [Abstract][Full Text] [Related]
13. Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.
Lundberg A; Lindström LS; Harrell JC; Falato C; Carlson JW; Wright PK; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Clin Cancer Res; 2017 Dec; 23(24):7512-7520. PubMed ID: 28972043
[No Abstract] [Full Text] [Related]
14. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
[TBL] [Abstract][Full Text] [Related]
15. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B.
Raj-Kumar PK; Liu J; Hooke JA; Kovatich AJ; Kvecher L; Shriver CD; Hu H
Sci Rep; 2019 May; 9(1):7956. PubMed ID: 31138829
[TBL] [Abstract][Full Text] [Related]
16. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
[TBL] [Abstract][Full Text] [Related]
17. Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.
Falato C; Tobin NP; Lorent J; Lindström LS; Bergh J; Foukakis T
Mol Oncol; 2016 Apr; 10(4):517-25. PubMed ID: 26651914
[TBL] [Abstract][Full Text] [Related]
18. TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays.
Lin CH; Chen IC; Huang CS; Hu FC; Kuo WH; Kuo KT; Wang CC; Wu PF; Chang DY; Wang MY; Chang CH; Chen WW; Lu YS; Cheng AL
Sci Rep; 2015 Dec; 5():17879. PubMed ID: 26671300
[TBL] [Abstract][Full Text] [Related]
19. Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.
Kumar N; Zhao D; Bhaumik D; Sethi A; Gann PH
BMC Cancer; 2019 Mar; 19(1):215. PubMed ID: 30849944
[TBL] [Abstract][Full Text] [Related]
20. A Novel Prognostic Signature of mRNA-lncRNA in Breast Cancer.
Liu Q; Wang Z; Kong X; Wang X; Qi Y; Gao R; Fang Y; Wang J
DNA Cell Biol; 2020 Apr; 39(4):671-682. PubMed ID: 32040341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]